Related Experiment Video
Updated: Feb 18, 2026

A Novel Light Damage Paradigm for Use in Retinal Regeneration Studies in Adult Zebrafish
Published on: October 24, 2013
A Combination of G Protein-Coupled Receptor Modulators Protects Photoreceptors from Degeneration
Tivadar Orban1, Henri Leinonen1, Tamar Getter1
1Department of Pharmacology, Cleveland Center for Membrane and Structural Biology, School of Medicine, Case Western Reserve University, Cleveland, Ohio (T.O., H.L., T.G., S.G., A.V., H.H.-T., T.S.K., P.D.K., K.P.); Research Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio (T.S.K., P.D.K.); and Polgenix Inc., Cleveland, Ohio (Z.D., W.S.).
Abstract:
Degeneration of retinal photoreceptor cells can arise from environmental and/or genetic causes. Since photoreceptor cells, the retinal pigment epithelium (RPE), neurons, and glial cells of the retina are intimately associated, all cell types eventually are affected by retinal degenerative diseases. Such diseases often originate either in rod and/or cone photoreceptor cells or the RPE. Of these, cone cells located in the central retina are especially important for daily human activity. Here we describe the protection of cone cells by a combination therapy consisting of the G protein-coupled receptor modulators metoprolol, tamsulosin, and bromocriptine. These drugs were tested in Abca4 mice, a preclinical model for retinal degeneration. The specificity of these drugs was determined with an essentially complete panel of human G protein-coupled receptors. Significantly, the combination of metoprolol, tamsulosin, and bromocriptine had no deleterious effects on electroretinographic responses of wild-type mice. Moreover, putative G protein-coupled receptor targets of these drugs were shown to be expressed in human and mouse eyes by RNA sequencing and quantitative polymerase chain reaction. Liquid chromatography together with mass spectrometry using validated internal standards confirmed that metoprolol, tamsulosin, and bromocriptine individually or together penetrate the eye after either intraperitoneal delivery or oral gavage. Collectively, these findings support human trials with combined therapy composed of lower doses of metoprolol, tamsulosin, and bromocriptine designed to safely impede retinal degeneration associated with certain genetic diseases (e.g., Stargardt disease). The same low-dose combination also could protect the retina against diseases with complex or unknown etiologies such as age-related macular degeneration.
Insights
This study shows a combination therapy using metoprolol, tamsulosin, and bromocriptine can protect cone cells, crucial for vision, from retinal degeneration. This approach offers potential for treating genetic and age-related eye diseases.
Area of Science:
- Ophthalmology
- Pharmacology
- Genetics
Background:
- Retinal degenerative diseases affect photoreceptor cells, retinal pigment epithelium (RPE), neurons, and glial cells.
- Cone cells, vital for daily activity, are often impacted in retinal degeneration.
- Existing treatments for retinal degeneration are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the protective effects of a combination therapy involving metoprolol, tamsulosin, and bromocriptine on cone cells.
- To evaluate the safety and efficacy of this drug combination in a preclinical model of retinal degeneration.
- To determine the ocular penetration and target engagement of the therapeutic agents.
Main Methods:
- Testing a combination therapy of metoprolol, tamsulosin, and bromocriptine in *Abca4* mice, a model for retinal degeneration.
- Assessing drug specificity against a comprehensive panel of human G protein-coupled receptors.
- Evaluating electroretinographic responses in wild-type mice to determine safety.
- Utilizing RNA sequencing and quantitative PCR to confirm target gene expression in ocular tissues.
- Employing liquid chromatography-mass spectrometry to quantify drug levels in the eye following administration.
Main Results:
- The combination therapy demonstrated protective effects on cone cells in the *Abca4* mouse model.
- The drugs showed specificity for their G protein-coupled receptor targets.
- No adverse effects on electroretinographic responses were observed in wild-type mice.
- Metoprolol, tamsulosin, and bromocriptine were confirmed to penetrate ocular tissues after systemic administration.
- Target receptors were found to be expressed in both human and mouse eyes.
Conclusions:
- The combination of metoprolol, tamsulosin, and bromocriptine shows promise for protecting cone cells against retinal degeneration.
- This therapy is a potential candidate for human clinical trials to treat genetic retinal diseases like Stargardt disease.
- The low-dose combination may also offer protection against age-related macular degeneration and other complex retinal conditions.
Related Concept Videos
Photoreceptors and Visual Pathways
GPCR Desensitization
Channel Rhodopsins
Rhodopsins belong to the family of cell surface proteins called G-protein coupled receptors,...
G-Protein Gated Ion Channels
Sensory...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Photoreceptors and Plant Responses to Light

